Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Bio (CBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 21,615
  • Shares Outstanding, K 4,310
  • Annual Sales, $ 400 K
  • Annual Income, $ -16,950 K
  • 36-Month Beta 1.74
  • Price/Sales 51.32
  • Price/Cash Flow 0.00
  • Price/Book 0.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.01 +24.19%
on 09/20/17
5.79 -13.99%
on 10/09/17
+0.91 (+22.36%)
since 09/19/17
3-Month
3.11 +60.13%
on 08/24/17
5.79 -13.99%
on 10/09/17
+0.57 (+12.93%)
since 07/19/17
52-Week
3.11 +60.13%
on 08/24/17
21.30 -76.62%
on 12/15/16
-9.12 (-64.68%)
since 10/19/16

Most Recent Stories

More News
Catalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia B

-- Orphan drug designation provides marketing exclusivity if approved by FDA --

CBIO : 4.98 (-0.70%)
Catalyst Biosciences Announces Successful Completion of First Subcutaneous Dosing Cohort in Ongoing Hemophilia B Clinical Trial

Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced that its collaborator ISU Abxis has completed dosing of the first subcutaneous cohort (N = 3, the second of up to five patient cohorts) in an ongoing...

CBIO : 4.98 (-0.70%)
Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program

-- CB 2679d/ISU304 has patent coverage in all key commercial territories --

CBIO : 4.98 (-0.70%)
Today's Research Reports on Trending Tickers: Athersys and Catalyst Biosciences

NEW YORK, NY / ACCESSWIRE / September 7, 2017 / After posting the worst daily drop in weeks on rising geopolitical tensions between North Korea and the from their worst daily drop in weeks, U.S. markets...

CBIO : 4.98 (-0.70%)
ATHX : 1.84 (-5.40%)
Catalyst Biosciences Announces Positive Factor IX Clinical Data

-- CB 2679d/ISU304 is approximately 22 times more potent than current hemophilia B therapy --

CBIO : 4.98 (-0.70%)
Financial Milestone Achieved in Catalyst's Subcutaneous Factor IX Program

Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a financial...

CBIO : 4.98 (-0.70%)
Catalyst Biosciences Announces Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing Model

-- Data support ongoing clinical trial in individuals with hemophilia B --

CBIO : 4.98 (-0.70%)
Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial

Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, and ISU Abxis Co Ltd. (KOSDAQ: 086890) a commercial-stage...

CBIO : 4.98 (-0.70%)
Catalyst Biosciences Announces Presentations on its Next-Generation Subcutaneous Hemophilia Product Candidates at the 2017 International Society on Thrombosis and Haemostasis (ISTH) Meeting

-- Factor IX oral presentation & Factor VIIa poster presentation --

CBIO : 4.98 (-0.70%)
Today's Research Reports on Stocks to Watch: Catalyst Biosciences and MEI Pharma

NEW YORK, NY / ACCESSWIRE / June 1, 2017 / U.S. markets dipped Wednesday, but still posted a monthly gain in May. The Dow Jones Industrial Average declined 0.10 percent to close at 21,008.65, up 0.46...

CBIO : 4.98 (-0.70%)
MEIP : 2.62 (+5.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic...

See More

Support & Resistance

2nd Resistance Point 5.27
1st Resistance Point 5.12
Last Price 4.98
1st Support Level 4.85
2nd Support Level 4.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart